3 most recent filings and news items mentioning CRVO. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/CRVO/news?limit=20"
Pull CRVO filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayCervoMed Inc. received an Innovation Passport for neflamapimod under the UK's ILAP program to accelerate its development for Lewy body dementia. Regulatory approval marks a significant step toward addressing this unmet medical need.
View filing at SEC.gov →CervoMed released new analyses from its Phase 2b trial reinforcing neflamapimod's efficacy. The data supports selecting the 50 mg dose for Phase 3, enhancing investor confidence in the company's dementia pipeline.
View filing at SEC.gov →CervoMed Inc. completed a registered direct offering of 2.5 million shares at $4.00 per share, raising $10 million gross proceeds for working capital and general corporate purposes. The funding supports the clinical-stage biotech's development of neflamapimod for age-related brai
View filing at SEC.gov →